Table 2.

Kidney function by assignment to placebo or RBX in long-term studies of diabetic eye diseasea

MeasurementPlaceboRBX 32 mg/dTotalP
NMean ± SDNMean ± SDNMean ± SD
Baseline
    eGFR (ml/min per 1.73 m2)57682.4 ± 26.057980.8 ± 26.0115581.6 ± 26.00.30
    calculated creatinine clearance (ml/min)570115.6 ± 46.4575113.0 ± 46.81145114.3 ± 46.60.35
    serum creatinine (mg/dl)5761.0 ± 0.35791.0 ± 0.411551.0 ± 0.30.22
Study end (after 33 to 39 mo of treatment)
    eGFR (ml/min per 1.73 m2)56171.1 ± 26.855770.4 ± 26.3111870.8 ± 26.50.67
    calculated creatinine clearance (ml/min)555101.4 ± 44.2553100.1 ± 45.01108100.7 ± 44.60.63
    serum creatinine (mg/dl)5611.2 ± 0.75571.2 ± 0.811181.2 ± 0.70.56
Change (after 33 to 39 mo of treatment)
    eGFR (ml/min per 1.73 m2)560−11.3 ± 19.4556−10.7 ± 19.81116−11.0 ± 19.60.61
    calculated creatinine clearance (ml/min)555−14.2 ± 26.0552−13.6 ± 27.31107−13.9 ± 26.60.69
    serum creatinine (mg/dl)5600.2 ± 0.55560.2 ± 0.611160.2 ± 0.60.90
  • a eGFR, estimated GFR; MDRD, Modification of Diet in Renal Disease. eGFR estimated by the MDRD formula. Creatinine clearance calculated by the Cockroft-Gault formula.